Novo Nordisk, under the direction of its Chief Executive Officer Lars Fruergaard Jorgensen, has outlined an ambitious strategy to strengthen its product portfolio through the acquisition of companies with drugs in early and mid-stage development.
This initiative will include operations with substantial investments, reaching up to several billion dollars.
Novo Nordisk's approach focuses on therapeutic areas where the company already has significant presence, such as diabetes, obesity, cardiovascular diseases and the broad spectrum of cardiometabolism.
Additionally, the company seeks to consolidate its position in rare blood disorders, such as hemophilia and sickle cell anemia, where it considers it has a solid position.
In a recent interview, Jorgensen noted the intention to seek smaller-scale agreements, mainly in phase 1 and 2 projects, with investments typically modest, on the order of a few billion dollars.
This strategy aligns with the idea of expanding Novo Nordisk's portfolio in an agile and efficient manner.
The company focuses on areas where it possesses "deep biological knowledge" and seeks to leverage a specific set of technologies, such as "protein engineering", a capability it has been developing over the years.
Despite these expansion ambitions, Jorgensen stressed that the company's research and development (R&D) engine remains intact, and emphasized that transformational operations are not expected in the short term.
This announcement comes following Novo Nordisk's recent investment of approximately 6,000 million dollars in one of its production facilities in Denmark.
Additionally, the acquisition of KBP Biosciences, a biotechnology company based in Singapore, for up to 1,300 million dollars, highlights Novo Nordisk's active strategy in expanding its portfolio through significant-sized agreements.
These initiatives position the company as a key player in the search for innovative solutions for various health conditions.
With information from: Forbes.
Receive all industry news in our weekly newsletter Dialéctica Científica.